Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)

PHASE3RecruitingINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

September 30, 2027

Conditions
Influenza Disease; Flu
Interventions
DRUG

Baloxavir Marboxil

"The antiviral baloxavir marboxil administered in one unique dose.~1 capsule (40 mg) if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg"

DRUG

Placebo

Patients in the placebo group will receive one unique dose of placebo. 1 capsule if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg.

Trial Locations (1)

1205

RECRUITING

Geneva University Hospitals, Geneva

All Listed Sponsors
collaborator

Swiss National Science Foundation

OTHER

collaborator

University Hospital, Geneva

OTHER

collaborator

University of Geneva, Switzerland

OTHER

collaborator

Ente Ospedaliero Cantonale, Ticino, Switzerland

OTHER

collaborator

Centre Hospitalier Universitaire Vaudois (Switzerland)

UNKNOWN

collaborator

Universitätspital Zürich, (Switzerland)

UNKNOWN

collaborator

University of Zurich

OTHER

lead

Dre Pauline Vetter

OTHER